MassHealth Givlaari (givosiran) Monitoring Program

Givlaari (givosiran) requires prior authorization (PA) and will be managed by the Givlaari Monitoring Program.

Agent	Food and Drug Administration (FDA)-approved Indications and Limitations of Use
Givlaari (givosiran)	• adults with acute hepatic porphyria (AHP).

Givlaari (givosiran)

Givlaari (givosiran) is a prescription aminolevulinate synthase 1-directed small interfering RNA (siRNA) used to treat acute hepatic porphyria (AHP) in adults. Givlaari is designed to reduce levels of neurotoxins, aminolevulinic acid (ALA) and porphobilinogen (PBG), associated with AHP attacks and symptoms. Givlaari is administered once a month by subcutaneous injection.

Givlaari Monitoring Program

Givlaari will require PA. Following PA approval, MassHealth Drug Utilization Review (DUR) will reach out to the prescriber to inform them of the Givlaari Monitoring Program. MassHealth DUR will be reaching out to prescribers annually as needed to monitor for ongoing clinical effectiveness and to confirm continued response.

- Givlaari [package insert]. Cambridge (MA): Alnylam Pharmaceuticals, Inc.; 2019 Nov.